GlassScriptPhysician profile
Aitsa Jimenez Velez
NPI 1891731675
$3,887.21
in general payments reported to CMS, 2019-2025
27 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.00 · 2022: $835 · 2023: $984 · 2024: $726 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,948 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.29 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $466.92 | 2022-2025 | Calquence, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $388.91 | 2019-2025 | Opdivo, Reblozyl, Breyanzi |
| Janssen Pharmaceuticals, INC | $387.48 | 2022-2025 | Erleada, Rybrevant, Akeega |
| Pbg Puerto Rico LLC | $308.31 | 2022-2025 | |
| Amgen INC. | $285.33 | 2022-2025 | Xgeva, Lumakras, Kyprolis |
| Abbvie INC. | $261.81 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $257.69 | 2022-2025 | Keytruda, Welireg |
| Eli Lilly Export S.A. Puerto Rico Branch | $215.18 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $213.02 | 2022-2024 | |
| Genzyme Corporation | $143.68 | 2022-2025 | |
| Genentech USA, INC. | $137.44 | 2022-2025 | Tecentriq, Perjeta, Kadcyla |
| Pfizer INC. | $120.11 | 2022-2023 | |
| Puma Biotechnology, INC. | $110.09 | 2023-2025 | Nerlynx |
| Regeneron Healthcare Solutions, INC. | $94.94 | 2024-2025 | Libtayo |
| Caris Mpi, INC. | $93.54 | 2025 | Mi Cancer Seek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $83.99 | 2023 | Erleada |
| Incyte Corporation | $68.26 | 2022-2025 | Pemazyre, Jakafi, Monjuvi |
| Sobi, INC | $42.53 | 2024-2025 | |
| Tempus Ai, INC | $35.35 | 2025 | Xt Cdx |
| Exelixis INC. | $24.83 | 2024 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $24.62 | 2022 | |
| Deciphera Pharmaceuticals INC. | $24.07 | 2023 | Qinlock |
| Gilead Sciences, INC. | $22.74 | 2025 | Trodelvy |
| Mirati Therapeutics, INC. | $21.95 | 2023 | Krazati |
| Morphosys, US INC. | $21.35 | 2023 | Monjuvi |
| Seagen INC. | $20.87 | 2022 | |
| Pharmaand Gmbh | $12.20 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aitsa Jimenez Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.